Oppenheimer & Co’s BioMarin Pharmaceuticals BMRN Stock Holding History

Oppenheimer & Co’s Portfolio BMRN Stock Details BMRN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$266K	Buy	+4,656	New	+$255K	﹤0.01%	1526
2026 Q1	–	Sell	-7,847	Closed	-$466K	–	1697
2025 Q4	$466K	Sell	7,847 -2,028	-21%	-$110K	0.01%	1101
2025 Q3	$535K	Buy	9,875 +728	+8%	+$41.6K	0.01%	1150
2025 Q2	$503K	Buy	9,147 +3,736	+69%	+$220K	0.01%	1149
2025 Q1	$383K	Buy	+5,411	New	+$364K	0.01%	1175
2024 Q2	–	Sell	-4,714	Closed	-$412K	–	1441
2024 Q1	$412K	Buy	4,714 +1,949	+70%	+$174K	0.01%	1063
2023 Q4	$267K	Buy	2,765 +71	+3%	+$6.28K	﹤0.01%	1188
2023 Q3	$238K	Sell	2,694 -602	-18%	-$53.6K	﹤0.01%	1211
2023 Q2	$286K	Buy	3,296 +369	+13%	+$34.7K	0.01%	1174
2023 Q1	$285K	Buy	+2,927	New	+$303K	0.01%	1140
2015 Q3	–	Sell	-11,831	Closed	-$1.62M	–	1361
2015 Q2	$1.62M	Buy	+11,831	New	+$1.47M	0.05%	475
2014 Q2	–	Sell	-3,214	Closed	-$219K	–	1415
2014 Q1	$219K	Sell	3,214 -2	-0.1%	-$147	0.01%	1193
2013 Q4	$226K	Buy	+3,216	New	+$218K	0.01%	1152

Other funds holding BMRN

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Norges Bank Oslo, Norway $1T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return

VPC

Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

Oppenheimer & Co's BMRN Position: Q2 2026 in Review

Oppenheimer & Co opened a new position in BioMarin Pharmaceuticals (BMRN) in Q2 2026: 4,656 shares worth $266K. The stake represents ﹤0.01% of the portfolio and ranks #1526 among its holdings. This is a return to the name: Oppenheimer & Co previously reported a position in BMRN as recently as Q4 2025.

Oppenheimer & Co first reported a position in BMRN in Q4 2013 and has held it in 13 quarters since. The position peaked at $1.62M in Q2 2015. 565 funds tracked by Wall St. Rank hold BMRN as of Q2 2026.

Oppenheimer & Co held 4,656 shares of BioMarin Pharmaceuticals worth $266K as of Q2 2026.
BioMarin Pharmaceuticals was a new Oppenheimer & Co position in Q2 2026.
BioMarin Pharmaceuticals made up ﹤0.01% of Oppenheimer & Co's portfolio in Q2 2026, its #1526 holding.
Oppenheimer & Co first reported a position in BioMarin Pharmaceuticals in Q4 2013 and has held it in 13 quarters since.
Oppenheimer & Co's BioMarin Pharmaceuticals position peaked at $1.62M in Q2 2015.
565 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q2 2026.

Based on Oppenheimer & Co's 13F filing for Q2 2026, filed 3 Aug 2026.